Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells 5,423 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 5,423 shares of Sight Sciences stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $2.78, for a total transaction of $15,075.94. Following the completion of the sale, the chief technology officer now owns 1,744,118 shares in the company, valued at approximately $4,848,648.04. This trade represents a 0.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The stock was sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Trading Up 0.3 %

SGHT stock traded up $0.01 during midday trading on Wednesday, hitting $2.90. 273,683 shares of the company's stock were exchanged, compared to its average volume of 282,912. Sight Sciences, Inc. has a 1-year low of $2.67 and a 1-year high of $8.45. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $147.20 million, a PE ratio of -2.84 and a beta of 2.57. The business has a 50-day simple moving average of $3.59 and a two-hundred day simple moving average of $5.35.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. On average, sell-side analysts predict that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Citigroup decreased their target price on shares of Sight Sciences from $5.80 to $4.60 and set a "neutral" rating on the stock in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Piper Sandler reissued a "neutral" rating and set a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. UBS Group began coverage on Sight Sciences in a research note on Friday, December 6th. They issued a "buy" rating and a $5.50 target price for the company. Finally, Morgan Stanley lowered their price target on shares of Sight Sciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Monday, November 11th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $4.72.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently made changes to their positions in the stock. KCK LTD. purchased a new stake in shares of Sight Sciences in the 4th quarter valued at $15,925,000. Barclays PLC lifted its position in shares of Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock worth $317,000 after purchasing an additional 38,248 shares in the last quarter. Millrace Asset Group Inc. purchased a new position in shares of Sight Sciences in the third quarter valued at approximately $874,000. Geode Capital Management LLC grew its holdings in shares of Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock valued at $4,941,000 after purchasing an additional 12,709 shares in the last quarter. Finally, State Street Corp increased its stake in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after buying an additional 95,843 shares during the period. Hedge funds and other institutional investors own 55.51% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.